In fact ∆N-p73 is overexpressed in several tumors, among them breast [41], ovary [42, 43], prostate cancers [44], melanoma [45], neuroblastoma [46] and hepatocellular carcinoma [47, 48] and in most cases, ∆N-p73 expression is associated with therapy failure, chemoresistance, lymph node metastasis, and vascular invasion [49]. Here, TP73 is linked to prostate cancer.